A carregar...
Cost-effectiveness analysis of adding ramucirumab to the first-line erlotinib treatment for untreated EGFR-mutated metastatic non-small cell lung cancer in China
OBJECTIVE: To investigate the cost-effectiveness of ramucirumab plus erlotinib compared with placebo plus erlotinib in the first-line setting for patients with EGFR-mutated metastatic non-small cell lung cancer (mNSCLC) from the Chinese healthcare system perspective. DESIGN: A Markov model consistin...
Na minha lista:
| Publicado no: | BMJ Open |
|---|---|
| Main Authors: | , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
BMJ Publishing Group
2020
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7692814/ https://ncbi.nlm.nih.gov/pubmed/33243806 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/bmjopen-2020-040691 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|